
# **Merit-based Incentive Payment System (MIPS)**

2023 Eligible Measure Applicability (EMA) and Denominator Reduction User Guide: Quality Performance Category in Traditional MIPS

Quality Payment

## Quality Payment



**Purpose:** This resource reviews the denominator reduction process available to clinicians, groups, virtual groups, and APM Entities with fewer than 6 measures available for reporting traditional MIPS.







### How to Use This Guide

## Quality Payment



### **Table of Contents**

The Table of Contents is interactive. Click on a Chapter in the Table of Contents to read that section.



You can also click on the icon on the bottom left to go back to the Table of Contents.

**Please Note:** This guide was prepared for informational purposes only and isn't intended to grant rights or impose obligations. The information provided is only intended to be a general summary. It isn't intended to take the place of the written law, including the regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

### **Hyperlinks**

Hyperlinks to the <u>Quality Payment Program website</u> are included throughout the guide to direct the reader to more information and resources.







Quality Payment

# What Are the 2023 Performance Period Submission Requirements for the Quality Performance Category in Traditional MIPS?

The quality performance category data submission requirements are to:

- Submit 6 quality measures (~200 finalized in MIPS plus hundreds of Qualified Clinical Data Registry (QCDR) measures are available for reporting) or a complete specialty measure set.
- 1 of these quality measures must be an outcome measure. If an outcome measure isn't available, then you must submit a high priority measure.

#### What Happens if I Don't Meet These Requirements?

If you submit fewer than 6 measures, or you submit 6 or more measures but no outcome or high priority measure, we apply a denominator reduction process to determine if you reported all measures related to a clinical topic or within a specialty set.

If we determine that you could have reported more measures, you'll receive 0 out of 10 points for each required measure that isn't submitted.

The denominator reduction process is only applied to clinicians, groups, virtual groups, or APM Entities that:


 Report their quality measures for traditional MIPS through Medicare Part B claims or submit MIPS CQMs.

We don't apply the denominator reduction process to submissions that include QCDR measures or electronic clinical quality measures (eCQMs).



## Quality Payment

#### **Denominator Reduction Paths**





#### **Quality Payment** PROGRAM

#### **How Do Denominator Reductions Work?**

- We check that you reported Medicare Part B claims measures or MIPS CQMs. 1.
- We determine whether you reported all the measures available for your chosen collection type related to a 2. clinical topic or in a specialty measure set with fewer than 6 measures.

Appendix A identifies the measures we have identified as related to specific clinical topics.

Appendix B identifies the specialty measure sets with fewer than 6 measures available for the Medicare Part B claims or MIPS CQM collection types.

### How Can Denominator Reductions Affect My Quality Performance Category Score?

Quality Data You Submitted	Impact to Quality Performance Category Score		
Fewer than 6	You may qualify for a <b>denominator reduction.</b>	Measures that don't meet data	
measures:	This means we would reduce the number of measures you're required to report.	completeness (70%) or case minimum requirements (20 denominator eligible instances will earn 0 out of 10 points (3 points for small practices).	
	Your denominator for the quality performance category is 10 x the number of required measures.		
No outcome or high priority measure	You may qualify to earn achievement points for all 6 submitted measures.		
	This means you wouldn't receive 0 out of 10 points for the unsubmitted outcome or high priority measure.		

### **No Denominator Eligible Instances (MIPS CQMs)**

If the MIPS eligible clinician or group doesn't have any denominator eligible instances for a measure related to the clinical topic (or in a specialty measure set with fewer than 6 measures available for your chosen collection type), submit the MIPS CQM as 0/0 (0s in the numerator and denominator). We'll exclude these measures from the denominator.

If there are any denominator eligible instances, the measure must be reported as usual.

No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.

# When Will I See Scoring Changes from a Denominator Reduction Applied to My Submission?

As announced in August 2023 through the QPP listserv and <u>this fact sheet</u>, we've removed preliminary scoring as of the 2023 submission period.

- Denominator reductions will be applied to your quality score when we release final score preview in June 2024.
- If you report MIPS CQMs and your submission qualifies for a denominator reduction, you'll see related messaging during submission.
- Small practices reporting Medicare Part B claims measures won't see this messaging during submission because we don't perform this evaluation on Medicare Part B claims measures until the submission period closes. This timeline lets us ensure that all claims have been processed and attributed to your quality submission.

If you reported all the measures (Medicare Part B claims or MIPS CQMs) available to you and don't see a denominator reduction when final score preview is released in June 2024, please contact the QPP Service Center as you may need to submit a targeted review. (Note that targeted reviews must be submitted within 60 days of the release of MIPS payment adjustments in final performance feedback.)

# Can We Choose to Submit Only the Measures Related to a Clinical Topic as Defined in <u>Appendix A</u>?

No. You should submit all quality measures that apply to your scope of practice and not limit your submission to those measures contained within the clinical topic. The EMA process was established to support clinicians and groups who may not have 6 quality measures available for, and applicable, to their practice.

# When Are the Specialty Measure Sets and EMA Clinically Related Measures Updated?

Every year, we update the specialty measure sets through the rulemaking process. We receive stakeholder input through the annual specialty set solicitation process and public comments made in the Federal Register.

Every year, we update the measures related to a clinical topic (EMA process) through a sub-regulatory process. We get stakeholder input through collaborative review and feedback.







### Help, Resources, and Version History

# Quality Payment

### Where Can You Go for Help?

Contact the Quality Payment Program Service Center by email at <u>QPP@cms.hhs.gov</u>, create a <u>QPP Service Center ticket</u>, or by phone at 1-866-288-8292 (Monday through Friday, 8 a.m. - 8 p.m. ET). To receive assistance more quickly, please consider calling during non-peak hours—before 10 a.m. and after 2 p.m. ET.

 Customers who are hearing impaired can dial 711 to be connected to a TRS Communications Assistant. Visit the <u>Quality Payment</u> <u>Program website</u> for other <u>help</u> <u>and support information</u>, to learn more about <u>MIPS</u>, and to check out the resources available in the <u>Quality Payment Program</u> <u>Resource Library</u>.



### Help, Resources, and Version History

### **Additional Resources**

The following resources are available on the **<u>QPP Resource Library</u>**:

- 2023 MIPS Quality User Guide (PDF)
- 2023 MIPS Quality Measures List (XLS)



**Quality Payment** 

, PROGRAM

### Help, Resources, and Version History

### **Version History**

If we need to update this document, changes will be identified here.



Date	Description	
03/16/2023	Original Posting.	
02/23/2024	Updated FAQ on slide 9 to indicate that denominator reductions will be applied when quality scores are released with final score preview. Preliminary scoring is no longer available beginning with the 2023 submission period.	



# Appendix A: MIPS Clinically Related Measures Grouped by Clinical Topic



#### **Appendix A: MIPS Clinically Related Measures Grouped Quality Payment** by Clinical Topic

Clinical Topic	MIPS CQM	Medicare Part B Claims
Anesthesiology Care	<ul> <li>404: Anesthesiology Smoking Abstinence</li> <li>424: Perioperative Temperature Management</li> <li>430: Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy</li> <li>463: Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)</li> </ul>	Not Applicable
CABG Care (C)	<ul> <li>164: Coronary Artery Bypass Graft (CABG): Prolonged Intubation</li> <li>167: Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure</li> <li>168: Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration</li> <li>445: Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)</li> </ul>	Not Applicable
Cardiac Stress Imaging (C)	<ul> <li>322: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients</li> <li>324: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients</li> </ul>	Not Applicable
Cataract Care	<ul> <li>191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery</li> <li>303: Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery</li> <li>304: Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery</li> <li>389: Cataract Surgery: Difference Between Planned and Final Refraction</li> </ul>	Not Applicable

(C) Denotes a change to the measures available for the clinical topic

(N) Denotes a new clinical topic.

**Note:** MIPS CQMs that don't have any eligible instances for a clinically related measure should be submitted as 0/0. No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.



PROGRAM

### Appendix A: MIPS Clinically Related Measures Grouped Quality Payment by Clinical Topic

<b>Clinical Topic</b>	MIPS CQM	Medicare Part B Claims
Computed Tomography	<ul> <li>360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies</li> <li>364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines</li> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> <li>436: Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques</li> </ul>	<ul> <li>405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions</li> <li>406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients</li> <li>436: Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques</li> </ul>
Diagnostic Imaging	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients</li> <li>Undergoing Bone Scintigraphy</li> </ul>	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy</li> </ul>
Endoscopy and Polyp Surveillance (C)	<ul> <li>185: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use</li> <li>320: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</li> <li>439: Age Appropriate Screening Colonoscopy</li> </ul>	<b>320:</b> Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
Interventional Radiology	<ul> <li>145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy</li> <li>409: Clinical Outcome Post Endovascular Stroke Treatment</li> <li>413: Door to Puncture Time for Endovascular Stroke Treatment</li> <li>465: Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries</li> </ul>	<b>145:</b> Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy

(C) Denotes a <u>change</u> to the measures available for the clinical topic

(N) Denotes a new clinical topic.

## Appendix A: MIPS Clinically Related Measures Grouped Quality Payment by Clinical Topic

Clinical Topic	MIPS CQM	Medicare Part B Claims
Pathology 1	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy Pathology Reporting</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>396: Lung Cancer Reporting (Resection Specimens)</li> <li>397: Melanoma Reporting</li> </ul>	<ul> <li>249: Barrett's Esophagus</li> <li>250: Radical Prostatectomy Pathology Reporting</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology</li> <li>Specimens)</li> <li>396: Lung Cancer Reporting (Resection Specimens)</li> <li>397: Melanoma Reporting</li> </ul>
Pathology 2 (N)	<ul> <li>249: Barrett's Esophagus</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>397: Melanoma Reporting</li> <li>491: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker</li> <li>Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or</li> <li>Small Bowel Carcinoma</li> </ul>	<ul> <li>249: Barrett's Esophagus</li> <li>395: Lung Cancer Reporting (Biopsy/Cytology Specimens)</li> <li>397: Melanoma Reporting</li> </ul>
Pathology – Skin Cancer	<b>397:</b> Melanoma Reporting <b>440:</b> Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician	<b>397:</b> Melanoma Reporting
Surgical Care	<ul> <li>355: Unplanned Reoperation within the 30 Day Postoperative Period</li> <li>357: Surgical Site Infection (SSI)</li> <li>358: Patient-Centered Surgical Risk Assessment and Communication</li> </ul>	Not applicable
Internal Eye Care	<ul> <li>141: Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care</li> <li>384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery</li> <li>385: Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery</li> </ul>	Not applicable

(C) Denotes a <u>change</u> to the measures available for the clinical topic

(N) Denotes a new clinical topic.







Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Allergy/ Immunology (C)	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Anesthesiology (C)	<ul> <li>404: Anesthesiology Smoking Abstinence</li> <li>424: Perioperative Temperature Management</li> <li>430: Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy</li> <li>463: Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)</li> <li>477: Multimodal Pain Management</li> </ul>	Not Applicable

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

(N) Denotes specialty sets <u>newly</u> identified as having fewer than 6 measures for the MIPS CQM and/or Medicare Part B claims measure collection types

**Note:** MIPS CQMs that don't have any eligible instances for a clinically related measure should be submitted as 0/0. No supporting documentation is required at submission, as you must attest that data you submit has been validated and is true, accurate, and complete to the best of your knowledge. If you're selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate, and complete.

When reporting specialty measure sets, you're only accountable for the measures available through your chosen collection type for the specialty measure set. For example:

- The Allery/Immunology specialty set is included in this appendix for the Medicare Part B claims measure collection type because only 2 of the 13 measures can be reported through Medicare Part B claims; however, all 13 measures can be reported as MIPS CQMs.
- The Hospitalist specialty set includes 1 measure if you're reporting Medicare Part B claims measures, and 4 measures if you're reporting MIPS CQMs.



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Audiology (N)	Not	134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
	Applicable	155: Falls: Plan of Care
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		261: Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness
Cardiology (N)	Not	047: Advance Care Plan
	Applicable	128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		236: Controlling High Blood Pressure
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Certified Nurse	Not Applicable	047: Advance Care Plan
Midwives (C)		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Clinical Social Work (C)	Not	047: Advance Care Plan
	Applicable	134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

(C) Denotes a change to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Dermatology (C)	Not Applicable	<b>226</b> : Preventive Care and Screening Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Diagnostic Radiology	Not applicable	<b>145:</b> Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy
		<b>147:</b> Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
		405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions
		<b>406:</b> Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients
		<b>436:</b> Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques
Electrophysiology	<b>392</b> : Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation	Not Applicable
	<b>393:</b> Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision	
Emergency Medicine (C)	Not Applicable	<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Gastroenterology (N)	Not Applicable	047: Advance Care Plan
		<b>128:</b> Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
		320: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
General Surgery (C)	Not Applicable	047: Advance Care Plan
		<b>128:</b> Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow- Up Documented

(C) Denotes a change to the measures available in an existing specialty set with fewer than 6 measures



Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Hospitalists (C)	<b>005</b> : Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	<b>047:</b> Advance Care Plan
	<b>008:</b> Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	
	047: Advance Care Plan	
	<b>130:</b> Documentation of Current Medications in the Medical Record	
Infectious Disease (C)	Not Applicable	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Interventional Radiology (C)	Not Applicable	<b>145:</b> Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy
Mental/Behavioral Health and	Not Applicable	<b>128:</b> Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
Psychiatry (N)		<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		181: Elder Maltreatment Screen and Follow-Up Plan
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a change to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Nephrology (N)	Not Applicable	<ul> <li>001: Diabetes: Hemoglobin A1c (HbA1c) Poor Control (&gt; 9%)</li> <li>047: Advance Care Plan</li> <li>226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention</li> </ul>
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Neurosurgical (C)	Not Applicable	<b>226</b> : Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Nutrition/ Dietician (C)	Not Applicable	<ul> <li>001: Diabetes: Hemoglobin A1c (HbA1c) Poor Control (&gt; 9%)</li> <li>128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan</li> <li>181: Elder Maltreatment Screen and Follow-Up Plan</li> <li>226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention</li> </ul>
Oncology/ Hematology (N)	Not Applicable	<ul> <li>047: Advance Care Plan</li> <li>134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan</li> <li>226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention</li> <li>250: Radical Prostatectomy Pathology Reporting</li> <li>317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented</li> </ul>

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Ophthalmology and Optometry	Not Applicable	<b>141:</b> Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
(C)		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Otolaryngology	Not	047: Advance Care Plan
(N)	Applicable	128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		155: Falls: Plan of Care
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Pathology	Not Applicable	249: Barrett's Esophagus
		250: Radical Prostatectomy Pathology Reporting
		<b>395:</b> Lung Cancer Reporting (Biopsy/Cytology Specimens)
		<b>396:</b> Lung Cancer Reporting (Resection Specimens)
		<b>397:</b> Melanoma Reporting
Pediatrics (C)	Not Applicable	<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan
Physical Medicine	Not Applicable	047: Advance Care Plan
(N)		128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		155: Falls: Plan of Care
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

(C) Denotes a change to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims
Physical Therapy/ Occupational Therapy (N)	Not Applicable	128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		155: Falls: Plan of Care
		181: Elder Maltreatment Screen and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Plastic Surgery	Not Applicable	128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
(C)		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		<b>317</b> : Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
Podiatry (C)	Not Applicable	128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		155: Falls: Plan of Care
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Pulmonology (N)	Not Applicable	047: Advance Care Plan
		128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		236: Controlling High Blood Pressure

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims	
Radiation Oncology (C)	<b>102:</b> Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
	<b>143:</b> Oncology: Medical and Radiation – Pain Intensity Quantified		
	<b>144:</b> Oncology: Medical and Radiation – Plan of Care for Pain		
	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention		
Skilled Nursing Facility (N)	Not Applicable	047: Advance Care Plan	
		155: Falls: Plan of Care	
		181: Elder Maltreatment Screen and Follow-Up Plan	
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
Speech Language Pathology (C)	<b>130:</b> Documentation of Current Medications in the Medical Record	<b>134:</b> Preventive Care and Screening: Screening for Depression and Follow-Up Plan	
	134: Preventive Care and Screening: Screening for	181: Elder Maltreatment Screen and Follow-Up Plan	
	Depression and Follow-Up Plan	<b>226:</b> Preventive Care and Screening: Tobacco Use:	
	<b>181:</b> Elder Maltreatment Screen and Follow-Up Plan	Screening and Cessation Intervention	
	182: Functional Outcome Assessment		
	<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention		

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures



Quality Payment

Specialty Measure Set	MIPS CQMs	Medicare Part B Claims	
Thoracic Surgery	Not Applicable	047: Advance Care Plan	-
(C)		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
Urgent Care (C)	Not Applicable	226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	1
		<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
Urology (C)	Not Applicable	047: Advance Care Plan	
		128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	
		134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan	
		226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
Vascular Surgery	Not Applicable	<b>317:</b> Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented <b>047:</b> Advance Care Plan	<
(N)			
		<b>128:</b> Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	
		<b>226:</b> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	
		236: Controlling High Blood Pressure	
		317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	

(C) Denotes a <u>change</u> to the measures available in an existing specialty set with fewer than 6 measures

